AIM
WINT

Acrospire Investment Management’s Windtree Therapeutics Inc WINT Stock Holding History

Acrospire Investment Management’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,800
Closed -$6K – 2690
2016
Q4 		$6K Buy
+4,800
New +$8.86K ﹤0.01% 2042

Other funds holding WINT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Acrospire Investment Management's WINT Position: Q1 2017 in Review

Acrospire Investment Management sold out of Windtree Therapeutics Inc (WINT) in Q1 2017, closing a stake of 4,800 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in WINT in Q4 2016 and held it in 1 quarter. The position peaked at $6K in Q4 2016. 26 funds tracked by Wall St. Rank hold WINT as of Q1 2017.

  • Acrospire Investment Management reported no remaining Windtree Therapeutics Inc position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 4,800 Windtree Therapeutics Inc shares in Q1 2017, an estimated $6K.
  • Acrospire Investment Management first reported a position in Windtree Therapeutics Inc in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Windtree Therapeutics Inc position peaked at $6K in Q4 2016.
  • 26 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.